Research Topics
| A WizniaSummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected childrenJacobo Abadi
Division of Infectious Diseases, Department of Pediatrics, Jacobi Medical Center and Albert Einstein College of Medicine, 1400 Pelham Parkway, Bronx, NY, USA
J Acquir Immune Defic Syndr 41:298-303. 2006..Therapy simplification by PTI may provide a practical option in patients intolerant of or failing PI-based highly active antiretroviral therapy...- Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS ClinA Wiznia
Pediatric HIV Services, Jacobi Medical Center, Bronx, New York 10461, USA
AIDS Res Hum Retroviruses 16:1113-21. 2000..A change in antiretroviral therapy to a protease inhibitor-containing regimen was associated with a virological response rate of approximately 50% for this patient population... - Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patientsAndrew Wiznia
Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
Pediatr Infect Dis J 26:799-805. 2007..Enfuvirtide is the only entry inhibitor approved for the treatment of human immunodeficiency virus (HIV)-1 infection. It is approved for use in adults and dosage recommendations exist for children aged 6 years or older... 
Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapyJoseph S Cervia
Albert Einstein College of Medicine, Bronx, NY 11030, USA
Pediatr Infect Dis J 29:1118-22. 2010....- Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected childrenJoseph A Church
Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, CA 90027, USA
Pediatr Infect Dis J 23:713-8. 2004..The safety and antiretroviral activity of enfuvirtide treatment of 24 weeks in HIV-1-infected children has been previously documented. Here we present the long term tolerability and safety of enfuvirtide... - Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403Jennifer R King
University of Alabama at Birmingham, Birmingham, USA
Pediatr Infect Dis J 24:880-5. 2005..Differences in tolerability between the 2 treatment groups were not identified. Systemic exposure of these drugs was similar to that reported in other HIV-infected children and adults... - Higher frequency of HIV-1-specific T cell immune responses in African American children vertically infected with HIV-1Elizabeth R Sharp
Gladstone Institute of Virology and Immunology, San Francisco General Hospital, University of California, 94158, USA
J Infect Dis 192:1772-80. 2005..01) than Hispanic children; this was significantly driven by robust responses in African American girls near the age of puberty, many of whom carried the human leukocyte antigen class I B*58 allele... - A behavioral and cognitive profile of clinically stable HIV-infected childrenMolly L Nozyce
Department of Pediatrics, Bronx Lebanon Hospital Center, Bronx, New York, USA
Pediatrics 117:763-70. 2006..The purpose of this research was to characterize behavioral and cognitive profiles of clinically and immunologically stable antiretroviral-experienced HIV-infected children... - Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infectionRam Yogev
Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL 60614 3394, USA
Pediatr Infect Dis J 21:119-25. 2002..Aim. To evaluate the safety, tolerance, antiviral activity and immunologic changes after the change to a three drug combination... - CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected childrenAkihiko Saitoh
Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California 92093 0672, USA
AIDS 21:2191-9. 2007.... 
Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjectsXavier Saez-Llorens
Infectious Disease Department, Hospital del Nino, Panama City, Panama
Pediatrics 121:e827-35. 2008....- Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353Y J Bryson
David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1752, USA
HIV Clin Trials 9:115-25. 2008..We studied the safety, antiviral effect, and pharmacokinetics of NFV and its M8 metabolite with two dosing regimens in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-infected pregnant women... - Switch from ritonavir to indinavir in combination therapy for HIV-1-infected childrenStephen I Pelton
Boston Medical Center, Boston, MA 02118, USA
Clin Infect Dis 40:1181-7. 2005.... - Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected childrenRita J Jeremy
Pediatric Clinical Research Center, Department of Pediatrics, School of Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA 94143 0105, USA
Pediatrics 115:380-7. 2005..Neuropsychological functioning and its correlation with viral load were investigated for previously treated HIV-infected children who underwent a change in treatment regimen... - Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1Paul Krogstad
University of California, Los Angeles School of Medicine, Departments of Pediatrics and Molecular and Medical Pharmacology, Los Angeles, CA, 90095, USA
Clin Infect Dis 34:991-1001. 2002..These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia... - Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infectionJohan K Sandberg
Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141, USA
J Virol 76:7528-34. 2002..These data indicate that the key immunoregulatory NKT-cell compartment is compromised in HIV-1-infected patients... - Generation of CD3+CD8low thymocytes in the HIV type 1-infected thymusMary E Keir
Biomedical Sciences Graduate Program, University of California, San Francisco 94143, USA
J Immunol 169:2788-96. 2002..We suggest that this HIV-1-initiated selection process may contribute to the generation of dysfunctional CD8(+) T cells in HIV-1-infected patients... - Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected childrenJoseph A Church
Department of Pediatrics, Children s Hospital Los Angeles and Keck School of Medicine, University of Southern California, 90027, USA
Pediatr Infect Dis J 21:653-9. 2002..The fusion inhibitor T-20 is the first in this new class, and the present study is the first to examine chronic s.c. administration of T-20 to HIV-1-infected children... - Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected childrenJennifer R King
The University of Alabama at Birmingham, Birmingham, Ala, USA
Antivir Ther 7:267-70. 2002.... - Prevalence of oral lesions and percent CD4+ T-lymphocytes in HIV-infected children on antiretroviral therapyChristopher Okunseri
Department of Community Dentistry, Montefiore Medical Center, Affiliate of the Albert Einstein College of Medicine, Bronx, New York 55455, USA
AIDS Patient Care STDS 17:5-11. 2003..001). Compared to previous studies, overall prevalence estimates of oral lesions in this study was low. Children with low CD4 percent had more oral lesions, consistent with results from other HIV studies... - HIV-specific CD8+ T cell function in children with vertically acquired HIV-1 infection is critically influenced by age and the state of the CD4+ T cell compartmentJohan K Sandberg
Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA 94141, USA
J Immunol 170:4403-10. 2003..The results are discussed in relation to differences between the neonatal and adult immune systems in the ability to respond to HIV infection... - Dental visits by pediatric HIV-infected medical patientsChristopher Okunseri
N Y State Dent J 69:26-9. 2003..The researchers believe that the study showed that a significant number of HIV-infected children on public insurance programs receiving consistent medical care had not visited any dental provider... - Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infectionCourtney V Fletcher
Pediatric AIDS Clinical Trials Group and the Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
Pharmacotherapy 24:453-9. 2004..To evaluate and describe the parameters and characteristics of different drug regimens in children infected with human immunodeficiency virus (HIV)... - Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapySharon A Nachman
Department of Pediatrics, State University of New York Health Science Center at Stony Brook, Stony Brook, NY 11794 8111, USA
Arch Pediatr Adolesc Med 156:497-503. 2002..Human immunodeficiency virus (HIV)-infected children often suffer from impaired growth. Highly active antiretroviral therapy (HAART) successfully reduces HIV 1 (HIV-1) RNA to 400 copies/mL or less in many children...